晚期CKD启动聚苯乙烯磺酸钠与胃肠道不良事件风险:一项全国性研究
启动SPS与严重胃肠道不良事件风险升高相关(调整HR 1.25,95%CI 1.05-1.49),按标签剂量处方者风险更高(HR 1.54,95%CI 1.09-2.17);也与轻微胃肠道事件风险升高相关(调整HR 1.11,95%CI 1.03-1.19)。
要点
- 晚期CKD患者启动SPS与严重胃肠道不良事件风险升高相关(调整HR 1.25)。
- 按标签剂量处方SPS者严重胃肠道事件风险更高(HR 1.54)。
- SPS启动也与轻微胃肠道事件风险升高相关(调整HR 1.11)。
核心结论
- 在晚期CKD患者中启动SPS与严重胃肠道并发症及胃肠道相关药物启用风险升高相关。
- 按标签剂量处方时严重胃肠道事件风险更高。
研究设计与样本
- 随访期间3690例启动SPS,采用时变暴露评估SPS启动与胃肠道不良事件的关联。
主要发现
- 随访期间记录202例严重胃肠道事件和1149例轻微胃肠道事件。
- SPS启动与严重胃肠道事件风险升高相关(调整HR 1.25,95%CI 1.05-1.49),主要归因于溃疡和穿孔。
- 按标签剂量处方者严重胃肠道事件风险更高(HR 1.54,95%CI 1.09-2.17)。
- SPS启动与轻微胃肠道事件风险升高相关(调整HR 1.11,95%CI 1.03-1.19),主要归因于新启用泻药。
- 59%的患者长期使用SPS,平均每年3次取药;85%的患者处方剂量低于产品标签规定。
临床怎么用
- 晚期CKD患者使用SPS管理高钾血症时,应警惕严重胃肠道并发症风险,尤其是按标签剂量处方时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite long-standing clinical use of sodium polystyrene sulphonate (SPS) for hyperkalaemia management in chronic kidney disease (CKD), its safety profile remains poorly investigated. METHODS: We undertook an observational analysis of nephrology-referred adults with incident CKD Stage 4+ in Sweden during 2006-16 and with no previous SPS use. We studied patterns of use and adverse events associated to SPS initiation during follow-up. Patterns of SPS use were defined by chronicity of treatment and by prescribed dose. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) associated with SPS initiation (time-varying exposure) for the risk of severe (intestinal ischaemia, thrombosis or ulceration/perforation) and minor (de novo dispensation of laxatives or anti-diarrheal drugs) gastrointestinal (GI) events. RESULTS: Of 19 530 SPS-naïve patients with CKD, 3690 initiated SPS during follow-up. A total of 59% took SPS chronically, with an average of three dispensations/year. The majority (85%) were prescribed lower dosages than specified on the product label. During follow-up, 202 severe and 1149 minor GI events were recorded. SPS initiation was associated with a higher incidence of severe adverse events [adjusted HR 1.25 95% CI 1.05-1.49)], particularly in those receiving per label doses [1.54 (1.09-2.17)] and mainly attributed to ulcers and perforations. SPS initiation was also associated with higher incidence of minor GI events [adjusted HR 1.11 (95% CI 1.03-1.19)], regardless of dose, and mainly accounted for by de novo dispensation of laxatives. CONCLUSIONS: Initiation of SPS in patients with advanced CKD is associated with a higher risk of severe GI complications as well as the initiation of GI-related medications, particularly when prescribed at per label doses.
引用
- Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2020. PMID: 31377791. doi:10.1093/ndt/gfz150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。